Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
FibroBiologics, Inc. Common Stock
Market Cap
$2.54M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$2.55M
Net Profit Margin
-257.33%
TTM Avg
-169.26%
3Y Avg
-42605.81%
5Y Avg
-28403.87%
Market Cap
$2.56M
Net Profit Margin
-131.76%
TTM Avg
-396.75%
3Y Avg
-403.38%
5Y Avg
-531.17%
Market Cap
$2.67M
Net Profit Margin
-123.38%
TTM Avg
-169.81%
3Y Avg
-184.41%
5Y Avg
-199.55%
Market Cap
$2.45M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.69M
Net Profit Margin
-2449.04%
TTM Avg
-339.09%
3Y Avg
-222.12%
5Y Avg
-170.97%
Market Cap
$2.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.36M
Net Profit Margin
-1578.79%
TTM Avg
-2023.10%
3Y Avg
-17008.17%
5Y Avg
-11338.78%
Market Cap
$2.32M
Net Profit Margin
-201355.37%
TTM Avg
-74928.77%
3Y Avg
-55011.63%
5Y Avg
-36705.99%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| FibroBiologics, Inc. Common Stock (FBLG) | $2.54M | 0.00% | 0.00% | 0.00% | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.55M | -257.33% | -169.26% | -42605.81% | -28403.87% |
| Jaguar Health, Inc. (JAGX)vs › | $2.56M | -131.76% | -396.75% | -403.38% | -531.17% |
| Nuwellis, Inc. (NUWE)vs › | $2.67M | -123.38% | -169.81% | -184.41% | -199.55% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| iSpecimen Inc. (ISPC)vs › | $2.69M | -2449.04% | -339.09% | -222.12% | -170.97% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Onconetix, Inc. (ONCO)vs › | $2.36M | -1578.79% | -2023.10% | -17008.17% | -11338.78% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -201355.37% | -74928.77% | -55011.63% | -36705.99% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.27M | -862.34% | -747.16% | -4673.17% | -3945.34% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
